Cargando…

Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management

BACKGROUND: Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Li-Ting, Tong, Yuan-Yuan, Liu, Jin-Ping, Feng, Zheng-Yi, Zhao, Ju, Guo, Sheng-Wen, Jin, Yu, Zhang, Pei-Yao, Li, Yi-Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710314/
https://www.ncbi.nlm.nih.gov/pubmed/34711715
http://dx.doi.org/10.1097/CM9.0000000000001643
_version_ 1784623124403191808
author Bai, Li-Ting
Tong, Yuan-Yuan
Liu, Jin-Ping
Feng, Zheng-Yi
Zhao, Ju
Guo, Sheng-Wen
Jin, Yu
Zhang, Pei-Yao
Li, Yi-Xuan
author_facet Bai, Li-Ting
Tong, Yuan-Yuan
Liu, Jin-Ping
Feng, Zheng-Yi
Zhao, Ju
Guo, Sheng-Wen
Jin, Yu
Zhang, Pei-Yao
Li, Yi-Xuan
author_sort Bai, Li-Ting
collection PubMed
description BACKGROUND: Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety of high-dosage perfusion. METHODS: A total of 146 neonates who underwent on-pump heart surgery with single-shot HTK perfusion were divided into two groups according to HTK dosages: a standard-dose (SD) group (n = 63, 40 mL/kg < HTK ≤ 60 mL/kg) and a high-dose (HD) group (n = 83, HTK >60 mL/kg). Propensity score matching (PSM) was performed to control confounding bias. RESULTS: The SD group had a higher weight (3.7 ± 0.4 vs. 3.4 ± 0.4 kg, P < 0.0001), a lower proportion of complete transposition of the great artery (69.8% vs. 85.5%, P = 0.022), a lower cardiopulmonary bypass (CPB) time (123.5 [108.0, 136.0] vs. 132.5 [114.8, 152.5] min, P = 0.034), and a lower aortic x-clamp time (82.9 ± 27.1 vs. 95.5 ± 26.0 min, P = 0.005). After PSM, 44 patients were assigned to each group; baseline characteristics and CPB parameters between the two groups were comparable. There were no significant differences in peri-CPB blood product consumption after PSM (P > 0.05). The incidences of post-operative complications were not significantly different between the two groups. There were no significant differences in ventilation time, intensive care unit stay, and post-operative hospital stay (P > 0.05). Follow-up echocardiography outcomes at 1 month, 3 to 6 months, and 1 year showed that left ventricular ejection fraction and end-diastolic dimension were comparable between the two groups. CONCLUSIONS: In neonatal on-pump cardiac surgery patients, single-shot HD (>60 mL/kg) HTK perfusion had a comparable heart protection effect and short-term post-operative prognosis as standard dosage perfusion of 40 to 60 mL/kg. Thus, this study provides supporting evidence of the safety of HD HTK perfusion.
format Online
Article
Text
id pubmed-8710314
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87103142021-12-28 Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management Bai, Li-Ting Tong, Yuan-Yuan Liu, Jin-Ping Feng, Zheng-Yi Zhao, Ju Guo, Sheng-Wen Jin, Yu Zhang, Pei-Yao Li, Yi-Xuan Chin Med J (Engl) Original Articles BACKGROUND: Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety of high-dosage perfusion. METHODS: A total of 146 neonates who underwent on-pump heart surgery with single-shot HTK perfusion were divided into two groups according to HTK dosages: a standard-dose (SD) group (n = 63, 40 mL/kg < HTK ≤ 60 mL/kg) and a high-dose (HD) group (n = 83, HTK >60 mL/kg). Propensity score matching (PSM) was performed to control confounding bias. RESULTS: The SD group had a higher weight (3.7 ± 0.4 vs. 3.4 ± 0.4 kg, P < 0.0001), a lower proportion of complete transposition of the great artery (69.8% vs. 85.5%, P = 0.022), a lower cardiopulmonary bypass (CPB) time (123.5 [108.0, 136.0] vs. 132.5 [114.8, 152.5] min, P = 0.034), and a lower aortic x-clamp time (82.9 ± 27.1 vs. 95.5 ± 26.0 min, P = 0.005). After PSM, 44 patients were assigned to each group; baseline characteristics and CPB parameters between the two groups were comparable. There were no significant differences in peri-CPB blood product consumption after PSM (P > 0.05). The incidences of post-operative complications were not significantly different between the two groups. There were no significant differences in ventilation time, intensive care unit stay, and post-operative hospital stay (P > 0.05). Follow-up echocardiography outcomes at 1 month, 3 to 6 months, and 1 year showed that left ventricular ejection fraction and end-diastolic dimension were comparable between the two groups. CONCLUSIONS: In neonatal on-pump cardiac surgery patients, single-shot HD (>60 mL/kg) HTK perfusion had a comparable heart protection effect and short-term post-operative prognosis as standard dosage perfusion of 40 to 60 mL/kg. Thus, this study provides supporting evidence of the safety of HD HTK perfusion. Lippincott Williams & Wilkins 2021-12-20 2021-10-26 /pmc/articles/PMC8710314/ /pubmed/34711715 http://dx.doi.org/10.1097/CM9.0000000000001643 Text en Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Articles
Bai, Li-Ting
Tong, Yuan-Yuan
Liu, Jin-Ping
Feng, Zheng-Yi
Zhao, Ju
Guo, Sheng-Wen
Jin, Yu
Zhang, Pei-Yao
Li, Yi-Xuan
Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
title Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
title_full Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
title_fullStr Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
title_full_unstemmed Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
title_short Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
title_sort comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710314/
https://www.ncbi.nlm.nih.gov/pubmed/34711715
http://dx.doi.org/10.1097/CM9.0000000000001643
work_keys_str_mv AT bailiting comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT tongyuanyuan comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT liujinping comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT fengzhengyi comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT zhaoju comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT guoshengwen comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT jinyu comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT zhangpeiyao comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement
AT liyixuan comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement